Amerise Biosciences Ltd

Amerise BioScie has shown minimal revenue generation, with net sales at zero from March 2020 to March 2025, and a significant decline in operating income from 9.01 crore in March 2022 to 0.19 crore in March 2025. While expenditures decreased and cash flow turned positive in March 2025, overall profitability remains weak, with profit after tax at only 0.01 crore.

Amerise BioScie is scheduled to announce its results on November 5, 2025.

As of 28-Oct, Amerise Biosciences Ltd is currently priced at 0.66, reflecting a recent 1.54% increase, but it has a year-to-date decline of -45.45%. Despite a strong short-term performance, concerns about declining investor participation may affect the sustainability of its recent gains.

As of 27-Oct, Amerise Biosciences Ltd is currently priced at 0.65, reflecting a recent short-term gain of 6.56%. However, it has significantly underperformed year-to-date and over the last three years, with declines of 46.28% and 38.68%, respectively, despite outperforming its sector recently.

As of 24-Oct, Amerise Biosciences Ltd is currently priced at 0.61, reflecting a recent upward trend but a significant year-to-date decline of 49.59%. Despite outperforming the Sensex in the short term, the stock shows mixed momentum and decreased investor participation, indicating potential challenges ahead.

As of 17-Oct, Amerise Biosciences Ltd's stock price is at 0.57, down 5.0% and has hit a 52-week low. The stock has declined for six consecutive days, underperformed its sector, and shows a year-to-date drop of 52.89%, indicating a bearish trend and decreased investor confidence.

As of 15-Oct, Amerise Biosciences Ltd's stock price is Rs. 0.61, down 1.61%, marking a new 52-week low and a total decline of 6.15% over the last four days. The stock is underperforming compared to the broader market, which has seen positive returns, and has a year-to-date decline of 49.59%.

As of 24-Sep, Amerise Biosciences Ltd is priced at Rs. 0.66, reflecting a downward trend with a 52-week low and significant declines of 10.81% over the past week and 45.45% year-to-date, despite increased investor interest. The stock's performance starkly contrasts with the benchmark Sensex, which has gained 4.58% year-to-date.

As of 23-Sep, Amerise Biosciences Ltd's stock price is Rs. 0.66, down 5.71%, marking a new 52-week low and underperforming its sector by 6.04%. The stock has declined 45.45% year-to-date, contrasting sharply with the Sensex's gain of 5.07%, indicating significant investor confidence issues.

As of 22-Sep, Amerise Biosciences Ltd is priced at 0.70 with no change, underperforming its sector and showing a year-to-date decline of 42.15%. The stock is trading below all key moving averages and has seen decreased investor participation, indicating significant challenges compared to the broader market.

As of 19-Sep, Amerise Biosciences Ltd is priced at 0.70, up 1.45% today, but has a year-to-date decline of 42.15%. The stock is underperforming relative to the market and its sector, with decreased investor participation and trading below key moving averages.

As of 18-Sep, Amerise Biosciences Ltd's stock price is Rs 0.69, down 6.76%, with significant underperformance reflected in a 1-week return of -8.00% and a year-to-date decline of 42.98%. The stock is trading below all moving averages and is close to its 52-week low, indicating a bearish trend amidst a positive broader market performance.

As of 17-Sep, Amerise Biosciences Ltd is experiencing a short-term price increase of 5.71%, but has a significant year-to-date decline of 38.84%. Despite outperforming the sector recently, declining investor participation raises concerns about its long-term prospects.

As of 15-Sep, Amerise Biosciences Ltd is priced at 0.70, down 2.78%, and has underperformed significantly with a year-to-date decline of 42.15%. The stock is trading below all major moving averages and has shown weaker performance compared to the benchmark indices.

As of 12-Sep, Amerise Biosciences Ltd's stock price is 0.72, down 4.0%, with a year-to-date decline of 40.50%. Despite a recent weekly gain of 2.86%, the stock has significantly underperformed compared to the Sensex, which has gained 4.82% year-to-date.

As of 11-Sep, Amerise Biosciences Ltd is experiencing a price increase to 0.75, reflecting a rise of 7.14%. Despite recent gains, the stock's significant year-to-date decline of 38.02% and mixed momentum indicate caution for investors.

As of 10-Sep, Amerise Biosciences Ltd is priced at 0.70, with no change and a year-to-date decline of 42.15%. Despite a recent increase in delivery volume by 127.57%, the stock continues to underperform its sector and the broader market.

As of 09-Sep, Amerise Biosciences Ltd is priced at 0.70 with no change, underperforming its sector and the broader market. The stock has declined 42.15% year-to-date, indicating significant challenges in attracting investor interest.

As of 08-Sep, Amerise Biosciences Ltd is priced at 0.70 with no change, underperforming its sector and trading below all moving averages. The stock has declined 15.66% over the past year and 42.15% year-to-date, with significantly reduced investor participation and poor performance compared to the benchmark Sensex.